NASDAQ · PRE
Healthcare · Medical - Diagnostics & Research
$22.47
Up+$2.07 (+10.15%)
Updated Oct 8, 2026, 1:10 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
PRE closed at $22.47 after 21 trading sessions, down 7.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $20.40 | $22.7999 | $20.35 | $22.47 | 283.4K |
| Oct 6, 2026 | $21.17 | $21.17 | $19.81 | $20.40 | 320.22K |
| Oct 5, 2026 | $20.64 | $21.36 | $20.10 | $20.96 | 156.38K |
| Oct 2, 2026 | $22.15 | $22.225 | $19.85 | $20.17 | 311.53K |
| Oct 1, 2026 | $23.28 | $23.6037 | $21.89 | $21.95 | 94.42K |
| Sep 30, 2026 | $22.83 | $23.50 | $22.57 | $23.13 | 67.31K |
| Sep 29, 2026 | $22.98 | $23.22 | $22.69 | $22.84 | 65.89K |
| Sep 28, 2026 | $22.76 | $23.075 | $22.42 | $22.76 | 74.35K |
| Sep 25, 2026 | $22.63 | $23.685 | $22.215 | $22.97 | 136.89K |
| Sep 24, 2026 | $22.71 | $23.53 | $22.13 | $22.93 | 254.2K |
| Sep 23, 2026 | $22.95 | $23.545 | $22.35 | $22.71 | 245.77K |
| Sep 22, 2026 | $24.00 | $24.00 | $22.78 | $22.90 | 240.92K |
| Sep 21, 2026 | $24.70 | $25.01 | $23.76 | $24.34 | 112.65K |
| Sep 18, 2026 | $24.41 | $24.7509 | $23.81 | $24.19 | 123.91K |
| Sep 17, 2026 | $21.65 | $24.93 | $21.65 | $24.19 | 279.58K |
| Sep 16, 2026 | $23.08 | $23.17 | $21.55 | $22.02 | 247.04K |
| Sep 15, 2026 | $24.04 | $24.04 | $23.02 | $23.08 | 179.49K |
| Sep 14, 2026 | $22.78 | $24.53 | $22.50 | $24.12 | 162.95K |
| Sep 11, 2026 | $23.78 | $23.90 | $22.95 | $23.47 | 143.97K |
| Sep 10, 2026 | $24.09 | $24.70 | $23.34 | $23.66 | 188.22K |
| Sep 9, 2026 | $25.50 | $25.955 | $23.93 | $24.27 | 251.71K |
The latest Smart Investors Daily articles mentioning PRE.
Company
Market Activity
Research & News
PRE research
Company profile and research snapshot.
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | Craig-Hallum | Buy | — |
| Aug 27, 2026 | B. Riley Securities | Buy | — |
| Jul 15, 2026 | Benchmark | Buy | — |
| Jun 16, 2026 | Benchmark | Buy | — |
| Mar 16, 2026 | Lake Street | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 7, 2026
– Reuters cites Dow Jones interview
Benzinga · Sep 21, 2026
Prenetics Global (NASDAQ:PRE) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Benzinga · Sep 17, 2026
Craig-Hallum analyst Eric Des Lauriers initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $40.
Benzinga · Aug 27, 2026
B. Riley Securities analyst Jeff Van Sinderen initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $37.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRE.
